Contribution: Industrial Research Assistance Program – Contributions to Firms
AffinityImmuno Inc.
$49,337.00
Small molecule drug development for COVID
FY 2021-22 · 2021-06-01
Summary
Using a bioassay guided fractionation method, AffinityImmuno identified a natural product that is a potent inhibitor of SARS-CoV-2 spike protein binding to ACE2. Research on this natural product is to be accelerated and tested in an series of SARS-CoV-2 permissible cell lines and a hamster model of Covid-19 in order to determine whether to pursue a human health product.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Brackley|Brackley, Prince Edward Island, Canada
Recipient Type
For-profit organization
Business Number
807019971
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-06-01 | 2021-22 | $31,355.00 |
| 1 | 2021-06-01 | 2021-22 | $49,337.00 |
| 2 | 2021-06-01 | 2021-22 | $49,337.00 |
| 3 | 2021-06-01 | 2021-22 | $49,337.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 762 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 762 jours.
Agreement End Date
2024-07-31
Agreement Number
973631
Agreement Start Date
2021-06-01
Agreement Title
Small molecule drug development for COVID
Agreement Title (French)
Mise au point de médicaments à petites molécules pour la COVID
Agreement Type
Contribution
Agreement Value
$49,337.00
Amendment Date
2022-06-28
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Using a bioassay guided fractionation method, AffinityImmuno identified a natural product that is a potent inhibitor of SARS-CoV-2 spike protein binding to ACE2. Research on this natural product is to be accelerated and tested in an series of SARS-CoV-2 permissible cell lines and a hamster model of Covid-19 in order to determine whether to pursue a human health product.
Description (French)
En utilisant une méthode de fractionnement guidée par des essais biologiques, AffinityImmuno a mis en évidence un produit naturel qui est un inhibiteur puissant de la liaison de la protéine de spicule du SRAS-CoV-2 à l'ACE2. La recherche sur ce produit naturel doit être accélérée et testée dans une série de lignées cellulaires autorisées pour le SRAS-CoV-2 et dans un modèle de hamster atteint de Covid-19, afin de déterminer s'il faut poursuivre la recherche d'un produit pour la santé humaine.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Malpeque
Federal Riding (French)
Malpeque
Federal Riding Number
11004
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
807019971
Recipient City
Brackley|Brackley
Recipient Country
CA
Recipient Legal Name
AffinityImmuno Inc.
Recipient Postal Code
C1E 1C4
Recipient Province or Territory
PE
Recipient Type
F
Reference Number
172-2021-2022-Q1-973631
